SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic review

Table 8 Change in serum gamma-glutamyl transferase levels in individual studies

Study	Serum GGT (IU/L )			P value	P value between groups
	Group	Baseline	Study completion
Kuchay et al[11]	Empagliflozin	65.8 (36.1)	50.9 (24.6)	0.002	0.057
	Control	63.9 (45.3)	60.0 (39.0)	0.421
Ito et al[12]	Ipragliflozin	62.8 (58.3)	44.0 (38.3)	< 0.05	0.642
	Pioglitazone	71.6 (54.1)	48.8 (61.2)	< 0.05
Eriksson et al[14]	Placebo	32.4 (17.4)	+2.4 (9.6)1	-	-
	Omega-3 CA	54.0 (57.6)	+2.4 (12.0)1	-	Non-significant2
	Dapagliflozin	58.2 (43.2)	-4.8 (13.8)1	-	< 0.052
	O + D	40.2 (14.4)	-0.6 (13.8)1	-	Non-significant2
Ohki et al[15]	Ipragliflozin	75.0 (47.0-105.0)	60.0 (40.0-101.0)	0.03	-
Seko et al[16]	SGLT-2 inhibitor	61.7 (9.1)	58.7 (11.5)	0.051	-
	Sitagliptin	89.2 (11.8)	82.4 (11.9)	0.36
Gautam et al[17]	Canagliflozin	75.1 (31.8)	69.2 (26.2)	0.003	-
Sumida et al[18]	Luseogliflozin	62.4 (77.1)	48.2 (56.3)	0.003	-

¹Change from baseline.

²Compared to placebo.

CA: Carboxylic acid; GGT: Gamma-glutamyl transferase; O + D: Omega-3 carboxylic acid + Dapagliflozin; SGLT-2: Sodium glucose cotransporter-2.